Biotech Values

[mcbio]

That agreement only pertained to RG7128.

No clue what you're referring to here. RG7128 is VRUS' nuke that Roche has a separate and distinct agreement for apart from its prior agreement with ITMN for ITMN's HCV PI Danoprevir. I have no clue about the specifics of the arrangement between Roche and VRUS for RG7128 but, as has been discussed on here, the agreement between Roche and ITMN for ITMN's PI had an exclusivity portion to it to which Roche had to opt out of before it could license an HCV PI from another company.